Navigation Links
Lipid droplets lead a Spartin existence
Date:3/23/2009

Spartin, a protein linked to the neuronal disease Troyer syndrome, was thought to function in endocytosis. In the March 23, 2009 issue of the Journal of Cell Biology (www.jcb.org), Eastman et al. identify an unexpected role for Spartin in regulating the cell's lipid storage depots.

Cells transport excess fats into lipid droplets (LDs), where they are kept until needed as sources of energy, but little is known about LD formation and regulation. Spartin hadn't been connected to LDs. But Eastman et al. found that Spartin localizes to LDs and binds to a known LD protein called TIP47.

Spartin seems to regulate LD turnover: overexpressing or knocking-down the protein caused an increase in both the organelle's size and number. In turn, Spartin is regulated by ubiquitination by the ubiquitin ligase WWP1. Overexpressed WWP1 removed Spartin from LDs and promoted its degradation.

A truncated form of Spartin found in a rare neuronal disease called Troyer syndrome didn't localize to LDs or bind to TIP47. It remains to be seen whether defects in LD function are the root cause of the defects seen in Troyer patients, but author Paul Bieniasz points to precedents of defects in lipid turnover triggering neuronal disorders, such as mutations in the phospholipase NTE causing motor neuron disease.


'/>"/>

Contact: Rita Sullivan
news@rupress.org
212-327-8603
Rockefeller University Press
Source:Eurekalert  

Page: 1

Related biology news :

1. Story ideas from the Journal of Lipid Research
2. Chemists get grip on slippery lipids
3. Powerful integration of lipid metabolic profiling with gene expression analysis
4. Story ideas from the Journal of Lipid Research
5. Lipids in the brain an important factor for Alzheimers disease?
6. Story ideas from the Journal of Lipid Research
7. New genetic variants associated with lipid levels, risk for coronary artery disease
8. Europe-wide investment in lipid research will help tackle disease, says new report
9. People with heart disease still have trouble controlling blood lipid levels
10. The genetic heart of the lipids
11. Magnetic snakes control fluids, gravity-defying droplets, and solving a dragonfly mystery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Lipid droplets lead a Spartin existence
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology: